Syncom Formul.

Why is Syncom Formulations (India) Ltd falling/rising?

As of 09-Aug, Syncom Formulations (India) Ltd's stock price is rising to 13.44, reflecting a 1.9% increase due to strong relative performance and heightened investor interest, as indicated by a significant rise in delivery volume. The stock is above its 5-day and 20-day moving averages but below longer-term averages, suggesting potential resistance.

As of 09-Aug, Syncom Formulations (India) Ltd's stock price is rising, currently at 13.44, reflecting a change of 0.25 or 1.9% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 2.08% today, indicating strong relative performance. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 39.96% compared to the 5-day average, suggesting heightened interest from investors.<BR><BR>In terms of moving averages, the stock is currently higher than its 5-day and 20-day moving averages, which can be a positive signal for traders. However, it is important to note that it remains lower than its 50-day, 100-day, and 200-day moving averages, which may indicate some resistance at these longer-term levels.<BR><BR>Overall, the combination of improved performance relative to the sector and increased trading activity appears to be driving the stock's rise on this date.

Which are the latest news on Syncom Formul.?

When is the next results date for Syncom Formulations (India) Ltd?

The next results date for Syncom Formulations (India) Ltd is 11 August 2026.

The next results date for Syncom Formulations (India) Ltd is scheduled for 11 August 2026.

How big is Syncom Formul.?

As of 10th June, Syncom Formulations (India) Ltd has a market capitalization of 1,360.00 Cr, with recent net sales of 489.17 Cr and net profit of 76.43 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Syncom Formulations (India) Ltd has a market capitalization of 1,360.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 489.17 Cr, while the sum of Net Profit for the same period is 76.43 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 342.16 Cr, and Total Assets amount to 413.28 Cr.

Who are in the management team of Syncom Formul.?

The management team of Syncom Formul includes Kedarmal Bankda (Chairman & Wholetime Director), Vijay Shankarlal Bankda (Managing Director), Rinki Bankda (Whole-time Director), and several independent directors: Vinod Kumar Kabra, Krishna Das Neema, Praveen Jindal, Ruchi Jindal, Ritesh Kumar Lunkad, and Ankit Jain, along with Vaishali Agrawal as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Syncom Formul includes the following individuals:<BR><BR>1. **Kedarmal Bankda** - Chairman & Wholetime Director<BR>2. **Vijay Shankarlal Bankda** - Managing Director<BR>3. **Rinki Bankda** - Whole-time Director<BR>4. **Vinod Kumar Kabra** - Independent Director<BR>5. **Krishna Das Neema** - Independent Director<BR>6. **Praveen Jindal** - Independent Director<BR>7. **Ruchi Jindal** - Independent Director<BR>8. **Vaishali Agrawal** - Company Secretary & Compliance Officer<BR>9. **Ritesh Kumar Lunkad** - Independent Director<BR>10. **Ankit Jain** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Syncom Formul.?

Syncom Formul.'s peers include Windlas Biotech, Hester Bios, Amrutanjan Health, and others. It has average management risk, below average growth, and the lowest 1-year return at -36.94% among its peers.

Peers: The peers of Syncom Formul. are Windlas Biotech, Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Shukra Pharma., Jagsonpal Pharma, Lincoln Pharma., Fredun Pharma, Beta Drugs Ltd, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, Shukra Pharma., and Lincoln Pharma., while Average management risk is found at Windlas Biotech, Hester Bios, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Fredun Pharma, and Accent Microcell. Below Average management risk is present at Ind-Swift Labs. Growth is Excellent at Shukra Pharma. and Fredun Pharma, while Average growth is seen at Beta Drugs Ltd, and Below Average growth is noted at Windlas Biotech, Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., and Accent Microcell. Excellent capital structure is found at Windlas Biotech, Amrutanjan Healt, Shukra Pharma., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, Beta Drugs Ltd, and Accent Microcell, while Below Average capital structure is observed at Hester Bios, Ind-Swift Labs., and Fredun Pharma.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 211.49%, while Syncom Formul. has the lowest at -36.94%, indicating a significant negative performance compared to its peers. Additionally, Shukra Pharma., Amrutanjan Healt, and Syncom Formul. have negative six-month returns.

What does Syncom Formul. do?

Syncom Formulations (India) Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 135 Cr and a net profit of 25 Cr for March 2026. It has a market cap of INR 1,360 Cr, a P/E ratio of 17.00, and a return on equity of 18.41%.

Overview: <BR>Syncom Formulations (India) Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1988, Syncom Formulations was converted into a public limited company in June 1992. The latest reported quarterly results indicate net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 135 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,360 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.27 <BR>Return on Equity: 18.41% <BR>Price to Book: 3.30 <BR><BR>Contact Details: <BR>Address: 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd Mumbai Maharashtra : 400093 <BR>Tel: 91-22-30887744 <BR>Email: info@sfil.in / finance@sfil.in <BR>Website: http://www.sfil.in

Are Syncom Formulations (India) Ltd latest results good or bad?

Syncom Formulations (India) Ltd's latest results show strong profitability growth with a 42.28% increase in net profit, but revenue declined 9.05% year-on-year, raising concerns about sustainability. The company's reliance on non-operating income for a significant portion of profits suggests a cautious outlook despite improvements in margins.

Syncom Formulations (India) Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹25.17 crore, which is a significant increase of 42.28% year-on-year and a 33.10% rise from the previous quarter. This indicates strong profitability growth, which is a positive sign.<BR><BR>However, the revenue for the same quarter was ₹135.41 crore, reflecting a decline of 9.05% year-on-year, although it showed a recovery with a 17.60% increase compared to the previous quarter. This revenue volatility raises concerns about the sustainability of the company's core operations.<BR><BR>The operating margin improved to 16.25%, up 433 basis points from the previous year, showcasing better cost management. Additionally, the profit after tax (PAT) margin also saw a notable increase to 18.59%, up 671 basis points year-on-year.<BR><BR>Despite these positive indicators, there are significant concerns regarding the company's reliance on non-operating income, which constituted 43.18% of profit before tax in Q4 FY26. This raises questions about the quality of earnings and the sustainability of profit growth.<BR><BR>Overall, while the recent quarterly results show improvements in profitability and margins, the underlying challenges related to revenue contraction and dependence on non-operating income suggest a cautious outlook for the company. Investors should monitor future performance closely to assess whether these gains can be sustained.

Should I buy, sell or hold Syncom Formulations (India) Ltd?

Is Syncom Formul. overvalued or undervalued?

As of November 18, 2025, Syncom Formul. is fairly valued with a PE ratio of 24.53, compared to its peers like Sun Pharma at 36.56 and Cipla at 22.49, indicating reasonable pricing relative to its earnings growth potential despite underperforming the Sensex year-to-date.

As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued.<BR><BR>In comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth.

How has been the historical performance of Syncom Formul.?

Syncom Formul. has experienced significant fluctuations in financial performance, with net sales increasing to 465.01 Cr in March 2025 from 263.39 Cr in March 2024, but down from a peak of 21,966.32 Cr in March 2022. Despite recent improvements in key metrics, the company's historical data reflects volatility.

Answer:<BR>The historical performance of Syncom Formul. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Syncom Formul. reported net sales of 465.01 Cr for the year ending March 2025, a substantial increase from 263.39 Cr in March 2024 and 224.25 Cr in March 2023. However, this is a stark contrast to the exceptionally high net sales of 21,966.32 Cr recorded in March 2022. The company's total operating income mirrored this trend, reaching 465.01 Cr in March 2025, up from 263.39 Cr in the previous year. The total expenditure, excluding depreciation, was 410.88 Cr in March 2025, which also increased from 233.74 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 71.56 Cr, showing a rise from 43.18 Cr in March 2024, while profit before tax was reported at 65.51 Cr, up from 33.95 Cr. The profit after tax for March 2025 was 49.43 Cr, compared to 25.31 Cr in March 2024. The earnings per share (EPS) improved to 0.53 in March 2025 from 0.27 in March 2024. On the balance sheet, total assets increased to 413.28 Cr in March 2025 from 404.66 Cr in March 2024, while total liabilities also rose to 413.28 Cr from 404.66 Cr. The cash flow from operating activities was positive at 23.00 Cr in March 2025, a recovery from a negative cash flow of -5.00 Cr in March 2024. Overall, while Syncom Formul. has shown improvement in several financial metrics in the latest fiscal year, the historical data reflects a volatile performance with significant peaks and troughs.

Is Syncom Formul. technically bullish or bearish?

As of November 4, 2025, the market trend has shifted to a moderate bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bullish signal from Dow Theory.

As of 4 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. The KST is also bearish on the weekly chart, contributing to the overall bearish sentiment. The Dow Theory shows a mildly bullish signal on the weekly, but this is overshadowed by the predominant bearish indicators.

Who are the top shareholders of the Syncom Formul.?

The top shareholders of Syncom Formul include promoters led by Kedarmal Shankarlal Bankda, who holds 12.44%, and individual investors with a collective stake of 45.2%. Foreign institutional investors hold 0.11%, while mutual funds have a negligible presence, and there are no pledged promoter holdings.

The top shareholders of Syncom Formul include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kedarmal Shankarlal Bankda, with a stake of 12.44%. Additionally, individual investors collectively hold 45.2% of the shares. There are also 12 foreign institutional investors (FIIs) that hold a small portion, totaling 0.11%, while mutual funds have a negligible presence with 2 schemes holding 0.0%. There are no pledged promoter holdings reported.

What is the bonus history of the Syncom Formul.?

Syncom Formulations (India) Ltd announced a bonus issue on August 19, 2013, in the ratio of 5:2, meaning shareholders received five additional shares for every two shares held, with a record date of August 20, 2013.

Syncom Formulations (India) Ltd has a bonus history that includes a significant bonus issue announced on August 19, 2013. The company issued a bonus in the ratio of 5:2, with the record date for this bonus being August 20, 2013. This means that for every two shares held, shareholders received five additional shares. If you have any more questions about the company or its financial activities, feel free to ask!

Has Syncom Formul. declared dividend?

Yes, Syncom Formulations (India) Ltd has declared a 3% dividend, amounting to ₹0.03 per share, with an ex-date of September 9, 2022. However, the dividend yield is 0%, as it has not significantly contributed to returns, which have been primarily driven by strong price performance over various periods.

Syncom Formulations (India) Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Amount per share: 0.03<BR>- Ex-date: 09 Sep 2022<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.22%, the dividend return was 0%, leading to a total return of -6.22%.<BR><BR>Over the past year, the price return was 74.02%, with a dividend return of 0%, resulting in a total return of 74.02%.<BR><BR>In the last 2 years, the price return was 197.45%, the dividend return was 0%, culminating in a total return of 197.45%.<BR><BR>For the 3-year period, the price return was 142.43%, with a dividend return of 0.39%, giving a total return of 142.82%.<BR><BR>In the 4-year span, the price return was 150.84%, the dividend return was 0.37%, leading to a total return of 151.21%.<BR><BR>Over the last 5 years, the price return was 1789.19%, with a dividend return of 1.46%, resulting in a total return of 1790.65%.<BR><BR>Overall, while Syncom Formulations has declared a dividend, the yield remains at 0%, indicating that the dividend has not significantly contributed to returns in recent periods. The company has shown strong price returns over various periods, particularly in the long term.